ArticleMolecular psychiatry2021
[
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Neuropathologic correlates of cognitive impairment in Alzheimer's disease with discordant CSF biomarker profiles: co-pathologies in focus.Acta neuropathologica · 2025Article
- Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.Brain : a journal of neurology · 2025Article
- Subcortical tau deposition and plasma glial fibrillary acidic protein as predictors of cognitive decline in mild cognitive impairment and Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2025Article
- Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2025Review
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025Review
- Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.medRxiv : the preprint server for health sciences · 2024Article
- Advances in Molecular Psychiatry - March 2023: mitochondrial function, stress, neuroinflammation - bipolar disorder, psychosis, and Alzheimer's disease.Molecular psychiatry · 2023Article
- Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.Human brain mapping · 2023Article
- Tau PET burden in Brodmann areas 35 and 36 is associated with individual differences in cognition in non-demented older adults.Frontiers in aging neuroscience · 2023Article
- Medial Temporal Lobe Tau Aggregation Relates to Divergent Cognitive and Emotional Empathy Abilities in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
- Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.Frontiers in aging neuroscience · 2022Review
- Molecular Psychiatry special issue: advances in Alzheimer's disease.Molecular psychiatry · 2021Article
- Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.European journal of nuclear medicine and molecular imaging · 2021Review
- Regional changes with global brain hypometabolism indicates a physiological triage phenomenon and can explain shared pathophysiological events in Alzheimer's & small vessel diseases and delirium.American journal of nuclear medicine and molecular imaging · 2021Article
- Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- Network-based cortical atrophy predicts longitudinal clinical decline in sporadic behavioral variant frontotemporal dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cross-sectional studies have indicated potential for positron emission tomography (PET) in imaging tau pathology in Alzheimer's disease (AD); however, its prognostic utility remains unproven. In a longitudinal, multi-modal, prognostic study of cognitive decline, 20 patients with a clinical biomarker-based diagnosis in the AD spectrum (mild cognitive impairment or dementia and a positive amyloid-beta PET scan) were recruited from the Cognitive Clinic at Karolinska University Hospital. The participants underwent baseline neuropsychological assessment, PET imaging with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.